Wall Street brokerages predict that Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) will report sales of $300,000.00 for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Crinetics Pharmaceuticals’ earnings. The highest sales estimate is $550,000.00 and the lowest is $100,000.00. Crinetics Pharmaceuticals posted sales of $780,000.00 during the same quarter last year, which would indicate a negative year over year growth rate of 61.5%. The company is scheduled to report its next earnings results on Wednesday, March 11th.
According to Zacks, analysts expect that Crinetics Pharmaceuticals will report full-year sales of $1.06 million for the current fiscal year, with estimates ranging from $870,000.00 to $1.47 million. For the next financial year, analysts anticipate that the firm will post sales of $0.00. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Crinetics Pharmaceuticals.
Crinetics Pharmaceuticals (NASDAQ:CRNX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.03). Crinetics Pharmaceuticals had a negative return on equity of 29.27% and a negative net margin of 1,303.31%. The business had revenue of $0.51 million during the quarter, compared to the consensus estimate of $0.33 million.
Crinetics Pharmaceuticals stock traded up $0.19 during midday trading on Tuesday, hitting $18.56. The company’s stock had a trading volume of 25,900 shares, compared to its average volume of 63,139. The company has a quick ratio of 19.07, a current ratio of 19.07 and a debt-to-equity ratio of 0.04. The stock’s 50-day moving average price is $17.11 and its 200-day moving average price is $20.83. Crinetics Pharmaceuticals has a 12 month low of $14.33 and a 12 month high of $36.95. The company has a market capitalization of $457.62 million, a PE ratio of -8.32 and a beta of 0.88.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Orbimed Advisors LLC raised its holdings in Crinetics Pharmaceuticals by 6.5% during the 2nd quarter. Orbimed Advisors LLC now owns 2,039,282 shares of the company’s stock worth $50,982,000 after buying an additional 125,000 shares during the period. BlackRock Inc. raised its holdings in Crinetics Pharmaceuticals by 19.9% during the 2nd quarter. BlackRock Inc. now owns 932,424 shares of the company’s stock worth $23,312,000 after buying an additional 154,450 shares during the period. Vanguard Group Inc. raised its holdings in Crinetics Pharmaceuticals by 11.6% during the 2nd quarter. Vanguard Group Inc. now owns 504,539 shares of the company’s stock worth $12,614,000 after buying an additional 52,327 shares during the period. Janus Henderson Group PLC raised its holdings in Crinetics Pharmaceuticals by 2.3% during the 2nd quarter. Janus Henderson Group PLC now owns 499,542 shares of the company’s stock worth $12,489,000 after buying an additional 11,175 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in Crinetics Pharmaceuticals by 0.4% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 487,916 shares of the company’s stock worth $12,198,000 after buying an additional 1,786 shares during the period. Hedge funds and other institutional investors own 78.20% of the company’s stock.
Crinetics Pharmaceuticals Company Profile
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.
Read More: Why do companies issue monthly dividends?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.